Artículos de revistas sobre el tema "CYP3A4"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "CYP3A4".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Sun, Jie-Yu, Ze-Jun Xu, Fang Sun, Hui-Lei Guo, Xuan-Sheng Ding, Feng Chen y Jing Xu. "Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A". Current Pharmaceutical Design 24, n.º 24 (8 de noviembre de 2018): 2765–73. http://dx.doi.org/10.2174/1381612824666180829101836.
Texto completoNiwa, Toshiro, Kanae Narita, Ayaka Okamoto, Norie Murayama y Hiroshi Yamazaki. "Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5". Journal of Pharmacy & Pharmaceutical Sciences 22 (24 de julio de 2019): 332–39. http://dx.doi.org/10.18433/jpps30558.
Texto completoKamdem, Landry K., Frank Streit, Ulrich M. Zanger, Jürgen Brockmöller, Michael Oellerich, Victor W. Armstrong y Leszek Wojnowski. "Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus". Clinical Chemistry 51, n.º 8 (1 de agosto de 2005): 1374–81. http://dx.doi.org/10.1373/clinchem.2005.050047.
Texto completoMaruf, AA, MU Ahmed, M. A. K. Azad, M. Ahmed y A. Hasnat. "CYP3A Genotypes in Bangladeshi Tuberculosis Patients". Bangladesh Medical Research Council Bulletin 38, n.º 1 (22 de abril de 2012): 1–5. http://dx.doi.org/10.3329/bmrcb.v38i1.6978.
Texto completoKlees, Theresa Mariero, Pamela Sheffels, Kenneth E. Thummel y Evan D. Kharasch. "Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5". Anesthesiology 102, n.º 3 (1 de marzo de 2005): 550–56. http://dx.doi.org/10.1097/00000542-200503000-00012.
Texto completoLeskelä, S., E. Honrado, C. Montero-Conde, I. Landa, A. Cascón, R. Letón, P. Talavera et al. "Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer". Endocrine-Related Cancer 14, n.º 3 (septiembre de 2007): 645–54. http://dx.doi.org/10.1677/erc-07-0078.
Texto completoRaymond, Lendelle, Nikita Rayani, Grace Polson, Kylie Sikorski, Ailin Lian y Melissa A. VanAlstine-Parris. "Determining the IC50 Values for Vorozole and Letrozole, on a Series of Human Liver Cytochrome P450s, to Help Determine the Binding Site of Vorozole in the Liver". Enzyme Research 2015 (9 de noviembre de 2015): 1–4. http://dx.doi.org/10.1155/2015/321820.
Texto completoChang, Thomas KH y Rosita KY Yeung. "Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5". Canadian Journal of Physiology and Pharmacology 79, n.º 3 (1 de marzo de 2001): 220–26. http://dx.doi.org/10.1139/y00-130.
Texto completoBořek-Dohalská, Lucie y Marie Stiborová. "Cytochrome P450 3A activities and their modulation by α-naphthoflavone in vitro are dictated by the efficiencies of model experimental systems". Collection of Czechoslovak Chemical Communications 75, n.º 2 (2010): 201–20. http://dx.doi.org/10.1135/cccc2009525.
Texto completoFang, Jim y Jiuxue Song. "In vitro Characterization of the Oxidation of a Pyridinium Metabolite of Haloperidol by Human Placenta: The Effect of Smoking". Journal of Pharmacy & Pharmaceutical Sciences 15, n.º 4 (4 de octubre de 2012): 538. http://dx.doi.org/10.18433/j31w20.
Texto completoSaiz-Rodríguez, Miriam, Susana Almenara, Marcos Navares-Gómez, Dolores Ochoa, Manuel Román, Pablo Zubiaur, Dora Koller et al. "Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates". Biomedicines 8, n.º 4 (22 de abril de 2020): 94. http://dx.doi.org/10.3390/biomedicines8040094.
Texto completoHermann, Marie Louise Hiort y Mette Tingleff Skaanild. "Porcine foetal and neonatal CYP3A liver expression". Journal of Xenobiotics 1, n.º 1 (6 de mayo de 2011): 1. http://dx.doi.org/10.4081/xeno.2011.e1.
Texto completoBogacz, Anna, Monika Karasiewicz, Karolina Dziekan, Danuta Procyk, Małgorzata Górska-Paukszta, Aleksandra Kowalska, Przemysław Ł. Mikołajczak, Marcin Ożarowski y Bogusław Czerny. "Impact of Panax ginseng and Ginkgo biloba extracts on expression level of transcriptional factors and xenobiotic-metabolizing cytochrome P450 enzymes". Herba Polonica 62, n.º 1 (1 de marzo de 2016): 42–54. http://dx.doi.org/10.1515/hepo-2016-0004.
Texto completoWilliams, J. Andrew, Barbara J. Ring, Varon E. Cantrell, David R. Jones, James Eckstein, Kenneth Ruterbories, Mitchell A. Hamman, Stephen D. Hall y Steven A. Wrighton. "Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7". Drug Metabolism and Disposition 30, n.º 8 (1 de agosto de 2002): 883–91. http://dx.doi.org/10.1124/dmd.30.8.883.
Texto completoDiekstra, Meta, Heinz Josef Klümpen, Martijn P. J. K. Lolkema, Huixin Yu, Jacqueline S. L. Kloth, Hans Gelderblom, Ron H. N. van Schaik et al. "Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 4580. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4580.
Texto completoKrusekopf, Solveigh, Ivar Roots y Ullrich Kleeberg. "Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43". European Journal of Pharmacology 466, n.º 1-2 (abril de 2003): 7–12. http://dx.doi.org/10.1016/s0014-2999(03)01481-x.
Texto completoSalameh, Ghada, Kamal Al Hadidi y Mohammad El Khateeb. "Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population". Environmental Toxicology and Pharmacology 34, n.º 1 (julio de 2012): 23–33. http://dx.doi.org/10.1016/j.etap.2012.01.006.
Texto completoNovillo, Apolonia, Alicia Romero-Lorca, María Gaibar, Raoudha Bahri, Nourdin Harich, David Sánchez-Cuenca, Esther Esteban y Ana Fernández-Santander. "Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia". International Journal of Biological Markers 30, n.º 1 (enero de 2015): 148–51. http://dx.doi.org/10.5301/jbm.5000118.
Texto completoRoberts, Jessica K., Chad D. Moore, Erin G. Romero, Robert M. Ward, Garold S. Yost y Christopher A. Reilly. "Regulation of CYP3A genes by glucocorticoids in human lung cells". F1000Research 2 (13 de agosto de 2013): 173. http://dx.doi.org/10.12688/f1000research.2-173.v1.
Texto completoRoberts, Jessica K., Chad D. Moore, Erin G. Romero, Robert M. Ward, Garold S. Yost y Christopher A. Reilly. "Regulation of CYP3A genes by glucocorticoids in human lung cells". F1000Research 2 (8 de octubre de 2013): 173. http://dx.doi.org/10.12688/f1000research.2-173.v2.
Texto completoHuang, Lingfei, Junyan Wang, Jufei Yang, Huifen Zhang, Yinghua Ni, Zhengyi Zhu, Huijuan Wang et al. "Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome". Pharmacogenomics 20, n.º 15 (octubre de 2019): 1071–83. http://dx.doi.org/10.2217/pgs-2019-0090.
Texto completoElens, Laure, Rachida Bouamar, Dennis A. Hesselink, Vincent Haufroid, Ilse P. van der Heiden, Teun van Gelder y Ron HN van Schaik. "A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients". Clinical Chemistry 57, n.º 11 (1 de noviembre de 2011): 1574–83. http://dx.doi.org/10.1373/clinchem.2011.165613.
Texto completoÜn, İsmail, İ. Ömer Barlas, Nisa Uyar, Bahar Taşdelen y Naci Tiftik. "Distribution of drug-metabolizing enzymes coding genes CYP2D6, CYP3A4, CYP3A5 alleles in a group of healthy Turkish population". Turkish Journal of Biochemistry 44, n.º 2 (9 de julio de 2018): 142–46. http://dx.doi.org/10.1515/tjb-2017-0226.
Texto completoResál, T., K. Farkas y T. Molnár. "P546 The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype". Journal of Crohn's and Colitis 15, Supplement_1 (1 de mayo de 2021): S516. http://dx.doi.org/10.1093/ecco-jcc/jjab076.667.
Texto completoR Jada, S., X. Xiang, Q. Zhou, H. H Li, L. L Ooi y B. Chowbay. "Hepatic expression of CYP3A4 and CYP3A5 genes in Asians and implications for pharmacokinetic variations during chemotherapy". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 13124. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.13124.
Texto completoBellah, Sm Faysal, Maizbha Uddin Ahmed, Sikder Nahidul Islam Rabbi, Mohd Nazmul Hasan Apu, Md Siddiqul Islam, Mir Muhammad Nasir Uddin, Mohammad Safiqul Islam y Abul Hasnat. "Prostate Cancer Risk in Relation to CYP3A4 and CYP3A5 Genotypes in the Bangladeshi Population". Dhaka University Journal of Pharmaceutical Sciences 14, n.º 2 (28 de junio de 2016): 179–85. http://dx.doi.org/10.3329/dujps.v14i2.28508.
Texto completoEl-Shair, Sahar, Mohammad Al Shhab, Khaled Zayed, Moaath Alsmady y Malek Zihlif. "Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine's Blood Levels and Doses among Jordanian Kidney Transplanted Patients". Current Drug Metabolism 20, n.º 8 (24 de septiembre de 2019): 682–94. http://dx.doi.org/10.2174/1389200220666190806141825.
Texto completoKIVISTÖ, KARI T., GERHARD BOOKJANS, MARTIN F. FROMM, ERNST-ULRICH GRIESE, PETER MÜNZEL y HEYO K. KROEMER. "Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue". British Journal of Clinical Pharmacology 42, n.º 3 (septiembre de 1996): 387–89. http://dx.doi.org/10.1046/j.1365-2125.1996.42615.x.
Texto completoGoh, Boon-Cher, Soo-Chin Lee, Ling-Zhi Wang, Lu Fan, Jia-Yi Guo, Jatinder Lamba, Erin Schuetz et al. "Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies". Journal of Clinical Oncology 20, n.º 17 (1 de septiembre de 2002): 3683–90. http://dx.doi.org/10.1200/jco.2002.01.025.
Texto completoHsu, Mei-Hui y Eric F. Johnson. "Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4". Journal of Biological Chemistry 294, n.º 20 (29 de marzo de 2019): 8015–22. http://dx.doi.org/10.1074/jbc.ra119.007928.
Texto completoDu, Jing, Lan Yu, Lei Wang, Aiping Zhang, Anli Shu, Lingyun Xu, Mingsheng Xu et al. "Differences in CYP3A4⁎1G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations". Clinica Chimica Acta 383, n.º 1-2 (agosto de 2007): 172–74. http://dx.doi.org/10.1016/j.cca.2007.04.027.
Texto completoNowak, Jan Krzysztof, Bartłomiej Bancerz y Alicja Bartkowska-Śniatkowska. "CYP3A drug metabolism in the developmental age: recent advances". Journal of Medical Science 88, n.º 1 (12 de marzo de 2019): 58–61. http://dx.doi.org/10.20883/jms.2019.290.
Texto completoZhang, Jiang-Wei, Yong Liu, Jie Cheng, Wei Li, Hong Ma, Hong-Tao Liu, Jie Sun et al. "Inhibition of Human Liver Cytochrome P450 by Star Fruit Juice". Journal of Pharmacy & Pharmaceutical Sciences 10, n.º 4 (12 de octubre de 2007): 496. http://dx.doi.org/10.18433/j30593.
Texto completoHe, Qingfeng, Fengjiao Bu, Hongyan Zhang, Qizhen Wang, Zhijia Tang, Jing Yuan, Hai-Shu Lin y Xiaoqiang Xiang. "Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling". Pharmaceuticals 14, n.º 3 (27 de febrero de 2021): 198. http://dx.doi.org/10.3390/ph14030198.
Texto completoYu, Ai-Ming, Katsumi Fukamachi, Kristopher W. Krausz, Connie Cheung y Frank J. Gonzalez. "Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis". Endocrinology 146, n.º 7 (1 de julio de 2005): 2911–19. http://dx.doi.org/10.1210/en.2004-1248.
Texto completoIndra, Radek, Katarína Vavrová, Petr Pompach, Zbyněk Heger y Petr Hodek. "Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b5 Activity". Biomedicines 8, n.º 12 (28 de noviembre de 2020): 547. http://dx.doi.org/10.3390/biomedicines8120547.
Texto completoDeJonge, M., M. M. Woo, D. Van der Biessen, P. Hamberg, S. Sharma, L. C. Chen, N. Myke, L. Zhao, S. Hirawat y J. Verweij. "A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): 2501. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.2501.
Texto completoSeo, Hyung-Ju, Seung-Bae Ji, Sin-Eun Kim, Gyung-Min Lee, So-Young Park, Zhexue Wu, Dae Sik Jang y Kwang-Hyeon Liu. "Inhibitory Effects of Schisandra Lignans on Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyl Transferases in Human Liver Microsomes". Pharmaceutics 13, n.º 3 (10 de marzo de 2021): 371. http://dx.doi.org/10.3390/pharmaceutics13030371.
Texto completoGnedenko, O. V., A. S. Ivanov, E. O. Yablokov, S. A. Usanov, D. V. Mukha, G. V. Sergeev, A. V. Kuzikov et al. "Protein-protein interactions of cytochromes P450 3A4 and 3A5 with their intermediate redox partners cytochromes". Biomeditsinskaya Khimiya 60, n.º 1 (enero de 2014): 17–27. http://dx.doi.org/10.18097/pbmc20146001017.
Texto completoGnedenko, O. V., A. S. Ivanov, E. O. Yablokov, S. A. Usanov, D. V. Mukha, G. V. Sergeev, A. V. Kuzikov et al. "Protein-protein interactions of cytochromes P450 3A4 and 3A5 with their intermediate redox partners cytochromes b5". Biomeditsinskaya Khimiya 61, n.º 4 (2015): 468–74. http://dx.doi.org/10.18097/pbmc20156104468.
Texto completoFuruse, Maizumi, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani et al. "The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients". PLOS ONE 16, n.º 4 (22 de abril de 2021): e0250597. http://dx.doi.org/10.1371/journal.pone.0250597.
Texto completoMutawi, Thuraya M., Mohamed M. Zedan, Raida S. Yahya, Mahmoud M. Zakria, Mamdouh R. El-Sawi y Andrea Gaedigk. "Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population". Pharmacogenomics 22, n.º 6 (abril de 2021): 323–34. http://dx.doi.org/10.2217/pgs-2020-0140.
Texto completoJi, Seung-Bae, So-Young Park, Subin Bae, Hyung-Ju Seo, Sin-Eun Kim, Gyung-Min Lee, Zhexue Wu y Kwang-Hyeon Liu. "Comprehensive Investigation of Stereoselective Food Drug Interaction Potential of Resveratrol on Nine P450 and Six UGT Isoforms in Human Liver Microsomes". Pharmaceutics 13, n.º 9 (7 de septiembre de 2021): 1419. http://dx.doi.org/10.3390/pharmaceutics13091419.
Texto completoKohlrausch, Fabiana B., Ángel Carracedo y Mara H. Hutz. "Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians". Molecular Biology Reports 41, n.º 3 (18 de enero de 2014): 1453–60. http://dx.doi.org/10.1007/s11033-013-2990-8.
Texto completoMa, Wenjuan, Wei Wang, Xuhua Huang, Guangzhe Yao, Qi Jia, Jiayuan Shen, Huizi Ouyang, Yanxu Chang y Jun He. "HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach". Evidence-Based Complementary and Alternative Medicine 2020 (9 de marzo de 2020): 1–12. http://dx.doi.org/10.1155/2020/8603934.
Texto completoDoshi, Utkarsh y Albert P. Li. "Luciferin IPA–Based Higher Throughput Human Hepatocyte Screening Assays for CYP3A4 Inhibition and Induction". Journal of Biomolecular Screening 16, n.º 8 (10 de agosto de 2011): 903–9. http://dx.doi.org/10.1177/1087057111414900.
Texto completoTseng, Elaine, Robert L. Walsky, Ricardo A. Luzietti, Jennifer J. Harris, Rachel E. Kosa, Theunis C. Goosen, Michael A. Zientek y R. Scott Obach. "Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)". Drug Metabolism and Disposition 42, n.º 7 (15 de abril de 2014): 1163–73. http://dx.doi.org/10.1124/dmd.114.057000.
Texto completoSugimoto, Mitsushige, Daiki Hira, Masaki Murata, Takashi Kawai y Tomohiro Terada. "Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy". Antibiotics 9, n.º 10 (26 de septiembre de 2020): 645. http://dx.doi.org/10.3390/antibiotics9100645.
Texto completoYang, Liang, Yuguang Wang, Huanhua Xu, Guangyao Huang, Zhaoyan Zhang, Zengchun Ma y Yue Gao. "Panax ginseng Inhibits Metabolism of Diester Alkaloids by Downregulating CYP3A4 Enzyme Activity via the Pregnane X Receptor". Evidence-Based Complementary and Alternative Medicine 2019 (21 de marzo de 2019): 1–13. http://dx.doi.org/10.1155/2019/3508658.
Texto completoOda, Yutaka, Katsuji Furuichi, Kazuo Tanaka, Toyoko Hiroi, Susumu Imaoka, Akira Asada, Mitsugu Fujimori y Yoshihiko Funae. "Metabolism of a New Local Anesthetic, Ropivacaine, by Human Hepatic Cytochrome P450". Anesthesiology 82, n.º 1 (1 de enero de 1995): 214–20. http://dx.doi.org/10.1097/00000542-199501000-00026.
Texto completo